Advertisement

Tumor Markers in Prostatic Disease

  • A. W. Bruce
  • B. K. Choe
Part of the Clinical Practice in Urology book series (PRACTICE UROLOG)

Abstract

One of the current problems in the diagnosis of prostatic cancer is that there is no procedure which can detect early localized disease curable by surgery and that truly localized cancers can only be detected by rectal examination in 10%–20% of patients. Another problem is the variability of the natural history of the disease. Clinically, some tumors remain localized for long periods, producing few, if any symptoms or signs, and others disseminate widely before symptoms are manifested. Due to this, numerous grading systems, as well as highly sophisticated cytometric systems, have been introduced to correlate the morphologic parameters of the cancer cells with their biologic characteristics, such as growth rate and metastatic potential. In addition, various biochemical or immunochemical markers have been researched in the past, and some of the molecular markers of prostatic cancer have found a place in the clinical laboratory (Benson and Coffey 1983; Whitmore 1984).

Keywords

Prostatic Cancer Acid Phosphatase Benign Prostatic Hyperplasia Prostatic Cancer Patient Adenoid Cystic Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bartsch G, Rohr HP (1982) Stereology—a new method to assess normal and pathological growth of the prostate. In: Jacobi GH, Hohenfellner R (eds) Prostate cancer. Williams & Wilkins Co., Baltimore, pp 433–459Google Scholar
  2. Bates RJ, Chapman CM, Prout GR Jr, Ling CW (1982) Immunohistochemical identification of prostatic acid phosphatase: correlation of tumor grade with acid phosphatase distribution. J Urol 127: 574–580PubMedGoogle Scholar
  3. Benson MC, Coffey DS (1983) Prostate cancer research: current concepts and controversies. Semin Oncol 1: 323–330Google Scholar
  4. Bishop MC, Fellows GJ (1977) Urine hydroxyproline excretion: a marker of bone metastasis in prostatic carcinoma. Br J Urol 49: 711–716PubMedCrossRefGoogle Scholar
  5. Bodansky O (1972) Acid phosphatase. Adv Clin Chem 15: 43–147PubMedCrossRefGoogle Scholar
  6. Brandes D, Kirchheim D, Scott WW (1964) Ultrastructure of the human prostate: normal and neoplastic. Lab Invest 13: 1541–1566PubMedGoogle Scholar
  7. Brock DJH, Mayo O (1978) The biochemical genetics of man, 2nd edn. Academic PressGoogle Scholar
  8. Bruce AW, Mahan DE (1982) The role of prostatic acid phosphatase in the investigation and treatment of adenocarcinoma of the prostate. Ann NY Acad Sci 309: 110 - 121CrossRefGoogle Scholar
  9. Bruce AW, Mahan DE (1986) Acid phosphatase: its estimation and clinical significance. In: BlandyGoogle Scholar
  10. JP, Lytton B (eds) The prostate (BIMR Urology). Butterworth, Surrey pp 147–162Google Scholar
  11. Bruce AW, Mahan DE, Morales A, Clark AF, Belville WD (1979) An objective look at acid phosphatase determinations. Br J Urol 51: 213–217PubMedCrossRefGoogle Scholar
  12. Catalona WJ, Chretien P, Matthews W et al. (1973) Serum ribonuclease in urologic cancer. Relation to host immunocompetence. Urology 1: 577–581CrossRefGoogle Scholar
  13. Chatal JP, Daver A, Fleury-Govern MC et al. (1982) The value of prostatic acid phosphatase (PAP) in predicting lymph node metastases in patients undergoing pelvic lymphadenectomy for prostatic cancer (abstract No. 235 ). American Urological Association Annual Meeting, Kansas CityGoogle Scholar
  14. Choe BK, Rose NR (1982) Prostatic acid phosphatase: a marker for human prostatic adenocarcinoma. In: Busch H, Yeoman LC (eds) Tumor markers. Methods in Cancer Research. 19: 199–232. Academic Press, New YorkGoogle Scholar
  15. Choe BK, Pontes EJ, Dong MK, Rose NR (1980) Double antibody immunoenzyme assay for human prostatic acid phosphatase. Clin Chem 26: 1854–1859PubMedGoogle Scholar
  16. Chu TM (ed) (1981) Biochemical markers for cancer. Marcel Dekker, New YorkGoogle Scholar
  17. Chu TM, Wang MC, Kuciel R (1977) Enzyme markers in human prostatic carcinoma. Cancer Treat Rep 61: 193–200PubMedGoogle Scholar
  18. Cook WB, Fishman WH, Clard BG (1962) Serum acid phosphatase of prostatic origin in the diagnosis of prostatic carcinoma. Clinical evaluation of 2408 tests by the Fishman-Lerner method. J Urol 88: 281–287PubMedGoogle Scholar
  19. Cooper JF, Finkle WD (1980) Current experience with radioimmunoassay techniques for prostatic acid phosphatase. Prostate 1: 441–450PubMedCrossRefGoogle Scholar
  20. Cooper JF, Foti A, Herschman H, Finkle W (1978) A solid phase radioimmunoassay for prostatic acid phosphatase. J Urol 119: 388–391PubMedGoogle Scholar
  21. Dennis LJ, Prout GR (1963) Lactic dehydrogenase in prostatic cancer. Invest Urol 1: 101–111Google Scholar
  22. Diamond DA, Berry SJ, Jewett HJ et al. (1982) A new method to assess metastatic potential of human prostatic cancer: relative nuclear roundness. J Urol 128: 729–734PubMedGoogle Scholar
  23. Edwards JJ, Anderson NG, Tollaksen SL, Von Eschenbach AC, Guevara J Jr (1982) Proteins of human urine: II. Identification by two dimensional electrophoresis of a new candidate marker for prostatic cancer. Clin Chem 28: 160–163PubMedGoogle Scholar
  24. Fishman WH, Dast RM, Bonner CD, Leadbetter WF, Lerner F, Homburger F (1953) A new method for estimating serum acid phosphatase of prostatic origin applied to the clinical investigation of cancer of the prostate. J Clin Invest 32: 1034–1044PubMedCrossRefGoogle Scholar
  25. Fleishmann J, Catalona W, Fair W et al. (1982) Lack of value of radioimmunoassay for prostatic acid phosphatase as a screening test for early prostate cancer (abstract No. 233 ). American Urological Association Annual Meeting, Kansas CityGoogle Scholar
  26. Foti AG, Cooper JR, Herschmann H, Melvaez RR (1977) Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. N Engl J Med 297: 1357–1361PubMedCrossRefGoogle Scholar
  27. Frankel AE, Rouse RV, Wang MC, Chu TM, Herzenberg LA (1982) Monoclonal antibodies to human prostate antigen. Cancer Res 42: 3714–3718PubMedGoogle Scholar
  28. Goldberg DM, Deland FH (1984) Clinical studies of prostatic cancer imaging with radiolabeled antibodies against prostatic acid phosphatase. Urol Clin North Am 11: 277–281Google Scholar
  29. Grayhack JT, Wendel EF (1979) Carcinoma of the prostate. In Kendall AR, Karafin L (eds)Google Scholar
  30. Urology, vol 2. Harper and Row, Hagerstown, pp 1–32Google Scholar
  31. Griffiths JC (1980) Prostate-specific acid phosphatase: réévaluation of radioimmunoassay in diagnosing prostatic disease. Clin Chem 26: 433–436PubMedGoogle Scholar
  32. Hopkins SC, Nissenkorn I, Palmieri GMA, Ikard M, Moinuddin M, Soloway MS (1983) Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer. J Urol 129: 319–323PubMedGoogle Scholar
  33. Jobsis AC, DeVries GP, Anhold RRH, Sanders GTB (1978) Demonstration of prostatic origin of metastases. An immunohistochemical method for formaline-fixed embedded tissue. Cancer 41: 1788–1793PubMedCrossRefGoogle Scholar
  34. Killian CS, Vargas FP, Pontes EJ et al. (1981) The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor loan in prostate cancer. Prostate 2: 187–206PubMedCrossRefGoogle Scholar
  35. Kirckheim D, Brandes D, Bacon RL (1974) Fine structure and cytochemistry of human prostatic carcinoma. In: Brandes D (ed) Male accessory sex organs: structure and function in mammals. Academic Press, New York, pp 397–405Google Scholar
  36. Kuhajda FP, Mann RB (1984) Adenoid cystic carcinoma of the prostate, a case report with immunoperoxidase staining for prostate-specific acid phosphatase and prostate-specific antigen. Am J Clin Pathol 81: 257–260PubMedGoogle Scholar
  37. Kuriyama M, Wang MC, Papsidero LD et al. (1980) Quantitiation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 40: 4658–4662PubMedGoogle Scholar
  38. Kuriyama M, Wang MC, Lee CL et al. (1981) Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41: 3874–3876PubMedGoogle Scholar
  39. Kuriyama M, Wang MC, Lee CL et al. (1982) Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. J Natl Cancer Inst 68: 99–104PubMedGoogle Scholar
  40. Kurth KH, Binder A, ten Kate FJW (1982) Prostate cancer: value of histophotometric tissue diagnosis. In: Jacobi GH, Hohenfellner R (eds) Prostatic cancer. Williams & Wilkins, Baltimore, pp 461–470Google Scholar
  41. Lee CL, Killian CS, Murphy GP, Chur TM (1980) A solid phase immunoadsorbent assay for serum prostatic acid phosphatase. Clin Chim Acta 101: 209–216PubMedCrossRefGoogle Scholar
  42. Lee CL, Li CY, Jou YH, Murphy GP, Chu TM (1982) Immunochemical characterization of prostatic acid phosphatase with monoclonal antibodies. Ann NY Acad Sci 309: 52–61CrossRefGoogle Scholar
  43. Li CY, Lam WKW, Yam LT (1980) Immunohistochemical diagnosis of prostatic cancer with metastasis. Cancer 46: 706–712PubMedCrossRefGoogle Scholar
  44. Lillehoj HS, Choe BK, Rose NR (1982) Monoclonal antibodies to human prostatic acid phosphatase: probes for antigenic study. Proc Natl Acad Sci (USA) 79: 5061–5065CrossRefGoogle Scholar
  45. Lin MF, Lee CL, Wojcieazyn JW, Wang MC, Valenzuela LA, Murphy GP, Chu TM (1980) Fundamental biochemical and immunological aspects of prostatic acid phosphatase. Prostate 1: 415–425PubMedCrossRefGoogle Scholar
  46. Lippert MC, Bensimon H, Javadpour N (1982) Immunoperoxidase staining of acid phosphatase in human prostatic tissue. J Urol 128: 1114–1116PubMedGoogle Scholar
  47. Mahan DE, Doctor BPA (1979) A radioimmune assay for human prostatic acid phosphatase level in prostatic disease. Clin Biochem 12: 10–17PubMedCrossRefGoogle Scholar
  48. Mahan DE, Bruce AW, Manley PN, Franchi L (1980) Immunohistochemical evaluation of prostatic carcinoma before and after radiotherapy. J Urol 124: 488–491PubMedGoogle Scholar
  49. Mathes G, Richmond SG, Sprunt DS (1956) Use of L-tartrate in determining prostatic serum acid phosphatase. Report of 514 cases. J Urol 75: 143–150PubMedGoogle Scholar
  50. Moopan MU, Wax SH, Kim H, Wang JC, Tobin MS (1980) Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate. J Urol 123: 694–696Google Scholar
  51. Mostofi FK, Price EB Jr (1973) Malignant tumors of the prostate. In: Tumors of the male genital system. Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington, pp 218–225Google Scholar
  52. Murphy GP, Reynoso G, Kenny GM, Gaeta JG (1969) Comparison of total and prostatic fraction serum acid phosphatase levels in patients with differentiated and undifferentiated prostatic carcinoma. Cancer 23: 1309–1314PubMedCrossRefGoogle Scholar
  53. Nesbit RM, Baum WC, Mich AA (1951) Serum phosphatase determination in diagnosis of prostatic cancer. A review of 1150 cases. JAMA 145: 1321–1324Google Scholar
  54. Nobles ER Jr, Kerr WS Jr, Dutoit CH, Rourke GM (1957) Serum prostatic acid phosphatase level in patients with carcinoma of the prostate. JAMA 164: 2020–2025Google Scholar
  55. Ostrowski W (1980) Human prostatic acid phosphatase: physiochemical and catalytic properties In: Spring-Mills E, Hafaz ESE (eds) Male accessory sex glands. Elsevier/North-Holland Biomedic, Amsterdam, pp 197–213Google Scholar
  56. Papsidero LD, Croghan GA, Wang MC et al. (1983) Monoclonal antibody ( F5) to human prostate antigen. Hybridoma 2: 139–147PubMedCrossRefGoogle Scholar
  57. Pontes JE, Choe BK, Rose NR, Pierce JM Jr (1977) Indirect immunofluorescence for identification of prostatic epithelial cells. J Urol 117: 459–463PubMedGoogle Scholar
  58. Pontes JE, Choe BK, Rose NR, Pierce JM (1978) Bone marrow acid phosphatase in staging of prostatic cancer: how reliable is it? J Urol 119: 772–776PubMedGoogle Scholar
  59. Pontes JE, Choe BK, Rose NR, Ercole C, Pierce JM Jr (1981) Clinical evaluation of immunological methods for detection of prostatic acid phosphatase. J Urol 126:363–365PubMedGoogle Scholar
  60. Pontes JE, Chu TM, Slack N, Karr J, Murphy GP (1982) Serum prostatic antigen measurement in localized prostatic cancer: correlation with clinical course. J Urol 128: 1216–1218PubMedGoogle Scholar
  61. Prellwitz W, Ehrenthal W (1982) Serum and bone marrow acid phosphatase as a diagnostic marker in prostatic cancer. In: Jacobi GH, Hohenfellner R (eds) Prostatic cancer. Williams & Wilkins, Baltimore pp 129–162Google Scholar
  62. Scardino P (1982) Serum acid phosphatase assays and other tumour markers of prostatic cancer. In: Prostate cancer videoconference guide book. American Urology Association Office of Education, pp 109–113Google Scholar
  63. Schacht MJ, Garaett JE, Grayhack JT (1984) Biochemical markers in prostatic cancer. Urol Clin North Am 11: 253–267PubMedGoogle Scholar
  64. Schmidt JD, Slack NH, Chu TM, Murphy GP (1982) Placenta-like isoenzymes of alkaline phosphatase in prostatic cancer. J Urol 127: 457–459PubMedGoogle Scholar
  65. Shulman S, Mamrod L, Gonder MJ, Soanes WA (1964) The detection of prostatic acid phosphatase by antibody reactions in gel diffusion. J Immunol 93: 474–480PubMedGoogle Scholar
  66. Silverman LM, Dermer GB, Zwieg MH, Van Steirteghem AC, Tokes ZA (1979) Creatinine kinase BB: a new tumor associated marker. Clin Chem 25: 1432–1435PubMedGoogle Scholar
  67. Slack NH, Chu TM, Wajsman LZ, Murphy GP (1981) Carcinoplacental isoenzyme ( Regan) in carcinoma of the prostate. Cancer 47: 146–151PubMedCrossRefGoogle Scholar
  68. Sodeman TM, Batsakis JG (1977) Acid phosphatase in urologic pathology. In: Tannebaum M (ed) Urologie pathology. The prostate. Lea and Febiger, Philadelphia, pp 129–139Google Scholar
  69. Starling JJ, Seig SM, Beckett ML, Schellhammer PF, Ladaga LE, Wright GL Jr (1982) Monoclonal antibodies to human prostate and bladder turnour-associated antigens. Cancer Res 42: 3084–3089PubMedGoogle Scholar
  70. Starling JJ, Beckett ML, Wright G Jr (1984) Monoclonal antibodies to prostate adenocarcinoma antigens. In: Wright GL (ed) Monoclonal antibodies and cancer, Marcel Dekker, New York, pp 253–286Google Scholar
  71. Tannenbaum M (1977) Histopathology of the prostate gland. In: Tannenbaum M (ed) Urologic pathology—the prostate. Lea and Febiger, Philadelphia, pp 303–397Google Scholar
  72. Townsend RM (1977) Enzyme tests in diseases of the prostate. Ann Clin Lab SCi 7: 254–261PubMedGoogle Scholar
  73. Vihko P, Sajanti E, Janne O, Peltonen L, Vihko R (1978) Serum prostate-specific acid phosphatase development and validation of a specific radioimmunoassay. Clin Chem 24: 1915–1919PubMedGoogle Scholar
  74. Wajsman Z, Chu JM, Bross D et al. (1978) Clinical significance of serum alkaline phosphatase isoenzyme levels in advanced prostatic carcinoma. J Urol 199: 244–246Google Scholar
  75. Wang MC, Kuriyama M, Papsidero LD, Loor RM, Valenzeula LA, Murphy GP, Chu TM (1982) Prostate antigen of human cancer patients. In: Busch H, Yeoman LC (eds) Tumor markers. Methods in Cancer Research 19: 179–197. Academic Press, New YorkGoogle Scholar
  76. Ware JL, Paulson DE, Parks SF, Webb KS (1982) Production of monoclonal antibody of aPro 3 recognizing a human prostatic carcinoma antigen. Cancer Res 42: 1215–1222PubMedGoogle Scholar
  77. Watson RA, Tang DB (1980) The predictive value of prostatic acid phosphatase as a screening test for prostatic cancer. N Engl J Med 303: 497–499PubMedCrossRefGoogle Scholar
  78. Whitesel JA, Donohue RE, Mani JH et al. (1984) Acid phosphatase: influence on the management of carcinoma of the prostate. J Urol 131: 70–72PubMedGoogle Scholar
  79. Whitmore WFJ (1984) Natural history and staging of prostate cancer. Urol Clin North Am 11: 205–220PubMedGoogle Scholar
  80. Wilson JWL, Morales A, Bruce AW (1983) The prognostic significance of histological grading and pathological staging in carcinoma of the prostate. J Urol 130: 481–483PubMedGoogle Scholar
  81. Yam LT, Janckila AJ, Lam KW et al. (1981) Immunohistochemistry of prostatic acid phosphatase. Prostate 2: 97–107PubMedCrossRefGoogle Scholar
  82. Yam LT, Winkler CF, Janckila AJ et al. (1983) Prostatic cancer presenting as metastatic adenocarcinoma of undetermined origin: immunodiagnosis by prostatic acid phosphatase. Cancer 51: 283–287PubMedCrossRefGoogle Scholar
  83. Yamaura N, Makino M, Walsh LJ, Bruce AW, Choe BK (1985) Production of monoclonal antibodies against prostatic acid phosphatase by in vitro immunization of human spleen cells. J Immunol Meth 84: 105–116CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • A. W. Bruce
  • B. K. Choe

There are no affiliations available

Personalised recommendations